Skip to main content
OpenTrials
Completed

NCT Number: NCT01971359

Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study

This study is determining the clinical outcomes, based on neurological testing, for the parafascicular minimally invasive clot evacuation technique. We will collect data from the time of surgery up until 90 days post procedure. We will also be looking at financial data as well.

* H(0): there is no economic benefit to the system with early surgical intervention for ICH * Alternative Hypothesis:H(1) Assuming clinical equipoise, i.e., no benefit in clinical outcome with early surgical intervention (null hypotheses) H(0) is correct), the ability to accelerate the patients care from the entry point to the exit point will result in a significant economic advantage to the system through cost reduction.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Patients will be recruited form the neurology and neurosurgery services at OSF Saint Francis Medical Center. Potential subjects will be identified by the study team which will include all investigators and study coordinators. For those patients who have had the Mi Space procedure, the study team will obtain the patients or patient's surrogate consent for clinical data of hospitalization and follow ups. A secured, de-identified log will be kept of all patients screened, and reasons for exclusion will be documented. Around 65% of unselected patients with ICH (not stratified by baseline predicted risk) have a documented 30 day composite outcome of death or dependency under medical management. Reviews of other types of minimally-invasive ICH surgeries provides data that significantly improved outcomes (meta-analysis odds ratio 0.54(0.39, 0.76)). An odds ratio of 0.54 shows a reduction in risk from 65% to about 50% (15% absolute reduction). Assuming the new procedure is at least as effective than current conventional management, 50 patients provides 66% surety that a 95% 1-sided confidence interval will exclude the chance that the new procedure is worse than medical management. Alternatively, a method of framing this, based on an exact one-sided binomial test of a one-sample proportion and an alpha level of 5%, is that a sample size of 50 patients provides approximately 66% surety/power that the new procedure is superior to medical management (i.e., lower than 65% suffering from death or poor functional outcomes). The critical computed value for this particular test, to provide some initial evidence of superiority, are observing no more than 26 patients (out of 50) suffering from death or dependency under the surgical procedure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion Criteria:
  • Consecutive patients aged at 18-80 presenting with an acute symptomatic supratertorial primary ICH diagnosed by CT
  • Symptom onset to surgery <24 hours (target <8 hours)
  • Glascow Coma Score > 9
  • Hematoma Volume, between 10ml and 50ml.
  • Minimal or no ventricular extension (corresponding to 50% or less of each ventricle)
  • NIHSS of >4 or deterioration determined by a neurologist.

Exclusion criteria

  • Suspected secondary ICH
  • Infratentorial ICH
  • Isolated IVH
  • Uncorrected coagulopathy
  • Significant premorbid disability (mRS >1)
  • Hydrocephalus
  • Contraindication to safe surgical procedure as per neurosurgeon (justification for exclusion on this basis will be recorded)

Treatment and study plan

Primary outcomes

  1. 30-90 day outcomes

    Time frame: 30-90 days

    The primary objective is to compare the 30 day and 90 day clinical outcomes of patients who will undergo parafascicular ICH-evacuation procedure compared to historical outcomes (surgical and non-surgical).

Secondary outcomes

  1. Surgery success rates

    Time frame: 30-90 days

    Another objective will be to describe and quantify peri-operative complications following the parafascicular ICH evacuation. We will assess the success rates of; atraumatic access to the hematoma, effective removal of fibrotic clot by measuring residual hematoma, the ability to achieve hemostasis intra-operatively, and to compare postoperative re-bleeding rates against residual clot volume.

Other outcomes

  1. Financial outcomes

    Time frame: 30-90 days

    We also will be looking at the financial aspect of current medical management and minimally invasive surgeries compared to the parafascicular technique.

Sponsors and collaborators

Lead sponsor

OSF Healthcare System

Other

Registry information

Acronym: MISPACE

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Oct 29, 2013
Registry last updated
May 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.